111 related articles for article (PubMed ID: 28560442)
1. New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity.
Li X; Wu H; Ouyang X; Zhang B; Su X
Oncol Rep; 2017 Jul; 38(1):129-140. PubMed ID: 28560442
[TBL] [Abstract][Full Text] [Related]
2. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
3. Anticancer bioactive peptide-3 inhibits human gastric cancer growth by suppressing gastric cancer stem cells.
Yu L; Yang L; An W; Su X
J Cell Biochem; 2014 Apr; 115(4):697-711. PubMed ID: 24214799
[TBL] [Abstract][Full Text] [Related]
4. Anticancer bioactive peptide suppresses human gastric cancer growth through modulation of apoptosis and the cell cycle.
Su L; Xu G; Shen J; Tuo Y; Zhang X; Jia S; Chen Z; Su X
Oncol Rep; 2010 Jan; 23(1):3-9. PubMed ID: 19956858
[TBL] [Abstract][Full Text] [Related]
5. HZ08 reverse the aneuploidy-induced cisplatin-resistance in Gastric cancer by modulating the p53 pathway.
Tang X; Hu G; Xu C; Ouyang K; Fang W; Huang W; Zhang J; Li F; Wang K; Qin X; Li Y
Eur J Pharmacol; 2013 Nov; 720(1-3):84-97. PubMed ID: 24183976
[TBL] [Abstract][Full Text] [Related]
6. [Effect of ACBP-S on cell cycle and apoptosis in human gastric cancer cells].
Su XL; Ouyang XH; Xu GH; Shen J; Wang ZY
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):422-7. PubMed ID: 19024515
[TBL] [Abstract][Full Text] [Related]
7. iTRAQ‑based proteomics analysis of the therapeutic effects of combined anticancer bioactive peptides and oxaliplatin on gastric cancer cells.
Xu Y; Li X; Su X
Oncol Rep; 2020 Jan; 43(1):201-217. PubMed ID: 31746436
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of chloroquine in combination with Cisplatin in human gastric cancer xenografts.
Zhang HQ; Fang N; Liu XM; Xiong SP; Liao YQ; Jin WJ; Song RF; Wan YY
Asian Pac J Cancer Prev; 2015; 16(9):3907-12. PubMed ID: 25987058
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer.
Su X; Dong C; Zhang J; Su L; Wang X; Cui H; Chen Z
Cell Biosci; 2014 Feb; 4(1):7. PubMed ID: 24507386
[TBL] [Abstract][Full Text] [Related]
10. The newly synthesized anticancer drug HUHS1015 is useful for treatment of human gastric cancer.
Kaku Y; Tsuchiya A; Kanno T; Nakao S; Shimizu T; Tanaka A; Nishizaki T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):527-35. PubMed ID: 25567349
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells.
Park JK; Lee SH; Kang JH; Nishio K; Saijo N; Kuh HJ
Anticancer Drugs; 2004 Sep; 15(8):809-18. PubMed ID: 15494644
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
13. Peiminine serves as an adriamycin chemosensitizer in gastric cancer by modulating the EGFR/FAK pathway.
Tang Q; Wang Y; Ma L; Ding M; Li T; Nie Y; Gu Z
Oncol Rep; 2018 Mar; 39(3):1299-1305. PubMed ID: 29328433
[TBL] [Abstract][Full Text] [Related]
14. 19-peptide, a fragment of tumstatin, inhibits the growth of poorly differentiated gastric carcinoma cells in vitro and in vivo.
He Y; Jiang Y; Li YJ; Liu XH; Zhang L; Liu LJ; Shi H; Li HN; Ma YC; Jin XM
J Gastroenterol Hepatol; 2010 May; 25(5):935-41. PubMed ID: 20546447
[TBL] [Abstract][Full Text] [Related]
15. Salidroside could enhance the cytotoxic effect of L‑OHP on colorectal cancer cells.
Shi X; Zhao W; Yang Y; Wu S; Lv B
Mol Med Rep; 2018 Jan; 17(1):51-58. PubMed ID: 29115408
[TBL] [Abstract][Full Text] [Related]
16. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
19. miR-135a promotes gastric cancer progression and resistance to oxaliplatin.
Yan LH; Chen ZN; Li-Li ; Chen J; Wei WE; Mo XW; Qin YZ; Lin Y; Chen JS
Oncotarget; 2016 Oct; 7(43):70699-70714. PubMed ID: 27683111
[TBL] [Abstract][Full Text] [Related]
20. Anticancer bioactive peptide (ACBP) inhibits gastric cancer cells by upregulating growth arrest and DNA damage-inducible gene 45A (GADD45A).
Su LY; Xin HY; Liu YL; Zhang JL; Xin HW; Su XL
Tumour Biol; 2014 Oct; 35(10):10051-6. PubMed ID: 25015188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
